In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Constellation Pharmaceuticals Inc (CNST), with a price target of $18. The company’s shares closed yesterday at $8.30.
“Valuation and risks to achievement of target price. Our price target of $18/share is based on an equally-weighted composite of: (a) $19.6/share, as a 25x multiple of taxed and diluted $7.2 discounted back to FY19 at 28% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $16.5/ share (discounted cash flow analysis using a 20% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.5% and a 38.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Constellation Pharmaceuticals Inc with a $18 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.04 and a one-year low of $4.01. Currently, Constellation Pharmaceuticals Inc has an average volume of 64.15K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.